NO20001869L - FremgangsmÕte for behandling av Alzheimers sykdom - Google Patents

FremgangsmÕte for behandling av Alzheimers sykdom

Info

Publication number
NO20001869L
NO20001869L NO20001869A NO20001869A NO20001869L NO 20001869 L NO20001869 L NO 20001869L NO 20001869 A NO20001869 A NO 20001869A NO 20001869 A NO20001869 A NO 20001869A NO 20001869 L NO20001869 L NO 20001869L
Authority
NO
Norway
Prior art keywords
alzheimer
disease
procedure
treatment
Prior art date
Application number
NO20001869A
Other languages
English (en)
Norwegian (no)
Other versions
NO20001869D0 (no
Inventor
David Robert Howlett
Davina Elizabeth Mitchell
Original Assignee
Boehringer Mannheim Pharm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Mannheim Pharm Corp filed Critical Boehringer Mannheim Pharm Corp
Publication of NO20001869D0 publication Critical patent/NO20001869D0/no
Publication of NO20001869L publication Critical patent/NO20001869L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20001869A 1997-10-15 2000-04-11 FremgangsmÕte for behandling av Alzheimers sykdom NO20001869L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6236697P 1997-10-15 1997-10-15
PCT/US1998/021789 WO1999018794A1 (en) 1997-10-15 1998-10-15 Method for treating alzheimer's disease

Publications (2)

Publication Number Publication Date
NO20001869D0 NO20001869D0 (no) 2000-04-11
NO20001869L true NO20001869L (no) 2000-06-14

Family

ID=22042015

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20001869A NO20001869L (no) 1997-10-15 2000-04-11 FremgangsmÕte for behandling av Alzheimers sykdom

Country Status (16)

Country Link
US (1) US6358990B1 (ja)
EP (1) EP1024697A4 (ja)
JP (1) JP2001519364A (ja)
KR (1) KR100573352B1 (ja)
CN (1) CN1281334A (ja)
AU (1) AU751526B2 (ja)
BR (1) BR9814075A (ja)
CA (1) CA2305262A1 (ja)
HU (1) HUP0100024A3 (ja)
IL (1) IL135584A (ja)
NO (1) NO20001869L (ja)
NZ (1) NZ504419A (ja)
PL (1) PL339910A1 (ja)
TR (1) TR200001018T2 (ja)
WO (1) WO1999018794A1 (ja)
ZA (1) ZA989365B (ja)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10142175A1 (de) * 2001-10-09 2003-03-27 Eucro Europe Contract Res Gmbh Verwendung von ß-Adrenozeptor-Agonisten zur Behandlung von neurodegenerativen Erkrankungen
US8101209B2 (en) * 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
WO2003092622A2 (en) * 2002-04-30 2003-11-13 Sb Pharmco Puerto Rico Inc. Carvedilol monocitrate monohydrate
WO2004002472A1 (en) * 2002-06-27 2004-01-08 Sb Pharmco Puerto Rico Inc. Carvedilol hydrobromide
EA008384B1 (ru) * 2002-06-27 2007-04-27 Эс Би ФАРМКО ПУЭРТО РИКО ИНК. Фосфатные соли карведилола, их сольваты, композиции и способы лечения гипертензии, застойной сердечной недостаточности или стенокардии
EP1686967A4 (en) * 2003-11-25 2012-08-08 Smithkline Beecham Cork Ltd CARVEDILOL-FREE BASE, SALTS, WATER-FREE FORMS OR SOLVATES THEREOF, CORRESPONDING PHARMACEUTICAL COMPOSITIONS, CONTROLLED RELEASE FORMULAS AND TREATMENT OR DISPOSAL PROCEDURES
US7750036B2 (en) * 2003-11-25 2010-07-06 Sb Pharmco Puerto Rico Inc. Carvedilol salts, corresponding compositions, methods of delivery and/or treatment
EP1691789B1 (en) * 2003-11-25 2017-12-20 SmithKline Beecham (Cork) Limited Carvedilol free base, salts, anhydrous forms or solvate thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods
CN1991364A (zh) * 2005-12-26 2007-07-04 中国科学院上海生命科学研究院 预防和治疗阿尔兹海默症的g蛋白偶联受体拮抗剂
EP2007385A4 (en) * 2006-03-23 2010-08-18 Sinai School Medicine CARDIOVASCULAR COMPOSITION AND ITS USE FOR THE TREATMENT OF MORBUS ALZHEIMER
WO2008021552A2 (en) * 2006-08-18 2008-02-21 Duke University Biased ligands and methods of identifying same
US20090076116A1 (en) * 2007-09-13 2009-03-19 Protia, Llc Deuterium-enriched carvediolo
US8932557B2 (en) 2008-02-14 2015-01-13 Eli Lilly And Company Imaging agents for detecting neurological dysfunction
US20110046378A1 (en) 2008-02-14 2011-02-24 Siemens Medical Solutions Usa, Inc. Novel Imaging Agents for Detecting Neurological Dysfunction
CN103172643B (zh) * 2011-12-26 2016-03-02 中国医学科学院药物研究所 黄皮咔唑生物碱及其制备方法和其药物组合物与用途
CN102816107B (zh) * 2012-08-20 2015-06-03 东南大学 咔唑衍生物及其制备方法与用途
JP2016523918A (ja) * 2013-06-27 2016-08-12 シーダーズ−サイナイ メディカル センター 神経変性状態の予防および治療のためのアドレナリン受容体拮抗薬
CA3192905A1 (en) * 2020-09-17 2022-06-23 Sui Rong Wayne CHEN Methods of treating and/or preventing alzheimer's disease with r-carvedilol

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2815926A1 (de) * 1978-04-13 1979-10-18 Boehringer Mannheim Gmbh Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE3319027A1 (de) * 1983-05-26 1984-11-29 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren zur herstellung von optisch aktiven carbazol-derivaten, neue r- und s-carbazol-derivate, sowie arzneimittel, die diese verbindungen enthalten
US4845115A (en) * 1986-12-17 1989-07-04 Glaxo Group Limited Method of medical treatment
US4868190A (en) * 1988-12-27 1989-09-19 Hoechst-Roussel Pharmaceuticals, Inc. N-pyridinyl-9H-carbazol-9-amines
US4983608A (en) 1989-09-05 1991-01-08 Hoechst-Roussell Pharmaceuticals, Inc. N-substituted-4-pyrimidinamines and pyrimidinediamines
JPH0558998A (ja) * 1991-09-06 1993-03-09 Taisho Pharmaceut Co Ltd カルバゾール誘導体
MX9700696A (es) * 1994-07-27 1997-04-30 Sankyo Co Compuestos heterociclicos, utiles como productores de efecto aloesterico en receptores muscarinicos.
FR2724933A1 (fr) * 1994-09-22 1996-03-29 Pf Medicament Nouveaux ethers aromatiques derives d'indoles utiles comme medicaments
US5760069A (en) * 1995-02-08 1998-06-02 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 Method of treatment for decreasing mortality resulting from congestive heart failure
FR2731222A1 (fr) * 1995-03-02 1996-09-06 Pf Medicament Nouveaux derives de piperazine aminoindoles cycliques, leur procede de preparation et leur utilisation a titre de medicaments
HUP9900426A3 (en) * 1995-05-01 2001-12-28 Univ Pittsburgh Pittsburgh Amyloid binding azoderivatives, preparation thereof and use of these compounds for the antemortem diagnosis of alzheimer's disease and in vivo imaging and prevention of amyloid deposition

Also Published As

Publication number Publication date
JP2001519364A (ja) 2001-10-23
NZ504419A (en) 2002-11-26
AU1089799A (en) 1999-05-03
IL135584A (en) 2005-12-18
AU751526B2 (en) 2002-08-22
US6358990B1 (en) 2002-03-19
EP1024697A4 (en) 2007-05-02
CA2305262A1 (en) 1999-04-22
KR20010031108A (ko) 2001-04-16
CN1281334A (zh) 2001-01-24
HUP0100024A3 (en) 2002-12-28
BR9814075A (pt) 2000-09-26
EP1024697A1 (en) 2000-08-09
WO1999018794A1 (en) 1999-04-22
HUP0100024A2 (hu) 2001-07-30
KR100573352B1 (ko) 2006-04-25
NO20001869D0 (no) 2000-04-11
TR200001018T2 (tr) 2000-08-21
IL135584A0 (en) 2001-05-20
ZA989365B (en) 1999-04-15
PL339910A1 (en) 2001-01-15

Similar Documents

Publication Publication Date Title
CY2018020I2 (el) Θεραπεια της νοσου ρομρε
NO20026199D0 (no) Forbindelser for behandling av Alzheimers sykdom
FI962557A (fi) PLA2-inhibiittoreiden käyttö Alzheimerin taudin hoidossa
NO944928D0 (no) Fremgangsmåter for inhibering av Alzheimers sykdom
EP1043991A4 (en) TREATMENT OF ALZHEIMER DISEASE
NO965377L (no) Indolinonforbindelser for behandling av sykdommer
NO995221D0 (no) Sulfonamider for behandling av endotelinmedierte sykdommer
NO20001869L (no) FremgangsmÕte for behandling av Alzheimers sykdom
DE69630479D1 (de) Arzneimittel zur Behandlung von entzündlichen Herzkrankheiten
EE200300214A (et) Sulfoonamiidid endoteliini vahendatud haiguste ravimiseks
HUP0003852A3 (en) Use of highly selective butyrylcholinesterase inhibitors for the treatment and diagnosis of alzheimer's disease and dementias
NO20032007L (no) Radiofarmasöytika for diagnostisering av Alzheimers sykdom
FI953915A (fi) Dupuytrenin taudin lievittämiseen
BR9711225A (pt) Composi-{es de propentofilina transd-rmica para o tratamento do mal de alzheimer
NO20010953D0 (no) En fremgangsmÕte for behandling av stafylokokkal sykdom
NO20000771L (no) Anvendelse av fankinon for behandling av Alzheimers sykdom
PH31643A (en) 2-Oxidole-1-carboxamide pharmaceutical agents for the treatment of alzheimer's disease.
AU1405899A (en) Treatment for alzheimer's disease
EP1181550A4 (en) METHODS OF IDENTIFYING COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
NO20012612L (no) Isonipecotamider for behandlingen av integrin-formidlede sykdommer
NO991158D0 (no) FremgangsmÕte for behandling av amyotrofisk lateralsklerose
NO961180D0 (no) Transdermal anordning inneholdende (E)-2-(p-fluorfenetyl)-3-fluorallylamin for behandling av Alzheimers sykdom
GB9709416D0 (en) Methods for treatment of alzheimer's disease using azaspiranes
NO970127D0 (no) Topiske sammensetninger for behandling av hudsykdom
SI1007040T1 (en) Use of phanquinone for the treatment of alzheimer's disease